scholarly journals Cancers of the Appendix: Review of the Literatures

ISRN Oncology ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Carl Ruoff ◽  
Louay Hanna ◽  
Wanqing Zhi ◽  
Ghulamullah Shahzad ◽  
Vladimir Gotlieb ◽  
...  

Cancers of the appendix are rare. Most of them are found accidentally on appendectomies performed for appendicitis. When reviewed, majority of the tumors were carcinoid, adenoma, and lymphoma. Adenocarcinomas of appendix are only 0.08% of all cancers and the treatment remains controversial. Here we are reporting a 46-year-old male presented with symptoms of appendicitis, diagnosed with adenocarcinoma of the appendix. The patient was treated with appendectomy and refused further surgical intervention to complete hemicolectomy. Up to date, he remains asymptomatic. We performed literature review of the tumors of the appendix. Most of the benign conditions are treated with surgery alone. Lymphomas require CHOP-like chemotherapy and carcinoid syndrome treatment with somatostatin analogues. It is generally recommended that right hemicolectomy is the preferred treatment for adenocarcinoma of appendix. The role of chemotherapy is unclear due to lacking randomized trials but seems to be accepted if there is lymph node involvement or peritoneal seeding.

2005 ◽  
Vol 61 (3) ◽  
pp. 695-701 ◽  
Author(s):  
Rojymon Jacob ◽  
Alexandra L. Hanlon ◽  
Eric M. Horwitz ◽  
Benjamin Movsas ◽  
Robert G. Uzzo ◽  
...  

Author(s):  
Christina S. Baik ◽  
Eric Vallières ◽  
Renato G. Martins

Patients with confirmed stage IIIA non-small cell lung cancer (NSCLC) represent a very heterogeneous group which includes those with limited microscopic ipsilateral mediastinal lymph node involvement discovered after a surgical resection, as well as those who have radiologically evident bulky subcarinal lymph node involvement at presentation. Different therapeutic options in stage IIIA disease include neoadjuvant chemo- or chemoradiotherapy followed by surgery, primary surgery followed by adjuvant chemotherapy with or without sequential adjuvant radiation therapy or definitive chemoradiation without surgery. The roles of surgery and radiation in stage IIIA disease are controversial, and there is inadequate data from randomized trials to inform the optimal therapeutic strategy. In contrast, chemotherapy has a clear indication in the curative setting. Data from randomized trials indicates that cisplatin-based chemotherapy should be given in either adjuvant or neoadjuvant settings to patients who are undergoing curative surgical resection and who are candidates for cisplatin therapy. In definitive chemoradiotherapy, cisplatin-based therapy is recommended although a carboplatin-based regimen may be given if patients cannot receive cisplatin. Finally, all patients with stage IIIA NSCLC should be evaluated early in a multidisciplinary setting that includes medical and radiation oncologists and thoracic surgeons with experience in lung cancer therapy.


2017 ◽  
Vol 18 (6) ◽  
pp. 667-674.e1 ◽  
Author(s):  
Álvaro Quintanal-Villalonga ◽  
Andrés Carranza-Carranza ◽  
Ricardo Meléndez ◽  
Irene Ferrer ◽  
Sonia Molina-Pinelo ◽  
...  

1992 ◽  
Vol 28 (5) ◽  
pp. 733
Author(s):  
Seung Yon Baek ◽  
Moon Gyu Lee ◽  
Jin Cheon Kim ◽  
Kyoung Sik Cho ◽  
Yong Ho Auh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document